Canada - English - Health Canada

astrazeneca canada inc - metoprolol tartrate - tablet (extended-release) - 200mg - metoprolol tartrate 200mg - beta-adrenergic blocking agents

Canada - English - Health Canada

nu-pharm inc - metoprolol tartrate - tablet (extended-release) - 200mg - metoprolol tartrate 200mg - beta-adrenergic blocking agents

Canada - English - Health Canada

pro doc limitee - metoprolol tartrate - tablet (extended-release) - 200mg - metoprolol tartrate 200mg - beta-adrenergic blocking agents

Canada - English - Health Canada

pro doc limitee - metoprolol tartrate - tablet (extended-release) - 200mg - metoprolol tartrate 200mg - beta-adrenergic blocking agents

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol tartrate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; povidone; magnesium stearate - indications as at 23 november 2004 : oral therapy - hypertension, angina pectoris prophylaxis, suspected or definite myocardial infarction, migraine prophylaxis.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol tartrate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 23 nov 2004 : intravenous therapy - disturbances of cardiac rhythm , in particular supraventricular tachyarrhythmias.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; povidone; magnesium stearate - indications as at 23 november 2004 : oral therapy - hypertension, angina pectoris prophylaxis, suspected or definite myocardial infarction, migraine prophylaxis.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 190mg;   - modified release tablet - 190 mg - active: metoprolol succinate 190mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 47.5mg;   - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - metoprolol succinate 95mg;   - modified release tablet - 95 mg - active: metoprolol succinate 95mg   excipient: ethylcellulose hydrated silica hyprolose hypromellose light liquid paraffin macrogol 6000 microcrystalline cellulose sodium stearyl fumarate titanium dioxide - · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis. · paediatric hypertension